Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. 
The eradication of Helicobacter pylori (Hp) infection in duodenal ulcer and dyspepsia has been achieved using various therapy regimens.  The efficacy of protein pump inhibitor pantoprazole as part of these regimens has not been widely studied.  During a prospective randomized trial, 250 Hp positive patients with either duodenal ulcer, erosive bulbitis, or gastritis and dyspepsia were treated using 14 days of therapy 1) pantoprazole 40 mg daily and clarithromycin 500 mg b.i.d. ( PC), 2) pantoprazole 40 mg daily and clarithromycin 500 mg b.i.d.  plus amoxicillin 1 g b.i.d. ( PCA), or 3) bismuth subcitrate 120 mg t.i.d.,  roxithromycin 150 mg b.i.d.,  metronidazole 250 mg b.i.d.  plus ranitidin 300 mg (BRMR).  Hp status was assessed on 3 tests at the inclusion (2-specimen rapid urease test, 2-specimen histology, serology) and 2 tests (2-specimen rapid urease test, 2-specimen histology) 4 weeks after the end of the treatment.  The entry criteria was fulfilled in 250 patients, of whom 13 missed the control endoscopy.  The treatment had to be discontinued for adverse effects in 8 (10%) BRMR patients, and 1 (1%) PCA patients.  Compliance was 100% in the PC group.  All ulcers were healed at the end of the study with one exception in the BRMR group.  The best eradication rate of Hp was shown by the PCA group with 94.8% (n = 73/77) followed by the PC group with 82.5% (n = 66/80) and finally the BRMR with 67.6% (n = 48/71)-PCA:BRMR - p < 0.001; PC:BRMR-p < 0.001; PCA:PC-p < 0.05.  This study showed that triple therapy using PPI pantoprazole combined with antibiotics clarithromycin and amoxicillin was very effective in the eradication of Hp and treatment of duodenal ulcer with rare side effects.  The dual pantoprazole and clarithromycin therapy had the highest rate of patient compliance, but is less effective than triple therapy.  The combination of ranitidin with bismuth based triple therapy had the highest number of adverse events and the lowest rate of Hp eradication and therefore, should not be recommended.